Table 2.
Subgroup analysis for overall survival in cancer patients with higher MDSCs
| Subgroup analysis | No. of studies | No. of patients | Pooled HR(95%CI) | Heterogeneity | ||
|---|---|---|---|---|---|---|
| Fixed | Random | I2 | p-value | |||
| Region | ||||||
| Eastern | 13 | 936 | 2.47 (1.95,3.12) | 2.47 (1.95,3.12) | 0% | 0.892 |
| Western | 6 | 521 | 1.35 (1.18,1.54) | 2.37 (1.41,3.97) | 75.8% | 0.001 |
| Sample size | ||||||
| <50 | 7 | 225 | 2.67 (1.85,3.84) | 2.67 (1.85,3.84) | 0% | 0.786 |
| ≥50, < 100 | 9 | 680 | 2.26 (1.78,2.88) | 2.37 (1.78,3.14) | 18.9% | 0.275 |
| ≥100 | 3 | 552 | 1.27 (1.11,1.46) | 2.04 (0.95,4.37) | 74.5% | 0.020 |
| Cancer types | ||||||
| GI cancers | 8 | 631 | 1.36 (1.20,1.55) | 1.92 (1.36,2.72) | 54.2% | 0.033 |
| HCC | 3 | 367 | 2.41 (1.53,3.82) | 2.41 (1.53,3.82) | 0% | 0.965 |
| NKT | 2 | 64 | 6.02 (1.70,21.28) | 6.02 (1.70,21.28) | 0% | 0.670 |
| Melanoma | 3 | 214 | 2.24(1.50,3.35) | 3.87 (1.24,12.04) | 73.9% | 0.022 |
| Other types | 3 | 181 | 3.07 (1.91,4.92) | 3.07 (1.91,4.92) | 0% | 0.912 |
| Subtypes | ||||||
| Total-MDSCs | 10 | 765 | 1.40 (1.23,1.60) | 2.53 (1.63,3.94) | 68.4% | 0.001 |
| PMN-MDSCs | 5 | 487 | 2.32 (1.73,3.13) | 2.32 (1.73,3.13) | 0% | 0.912 |
| Mo-MDSCs | 4 | 205 | 2.08 (1.40,3.11) | 2.95 (1.34,6.51) | 45.9% | 0.136 |
| Cut-off value | ||||||
| <10 | 14 | 1024 | 1.46 (1.29,1.66) | 2.56 (1.79,3.67) | 64.3% | 0.001 |
| ≥10 | 5 | 433 | 2.23 (1.67,2.98) | 2.23 (1.67,2.98) | 0% | 0.527 |
| NOS score | ||||||
| <7 | 10 | 901 | 2.59 (2.02,3.31) | 2.59 (2.02,3.31) | 0% | 0.770 |
| ≥7 | 9 | 556 | 2.17 (1.45,3.25) | 1.36 (1.19,1.55) | 60.5% | 0.009 |